Crinetics Pharmaceuticals (CRNX) Operating Expenses (2017 - 2026)

Crinetics Pharmaceuticals' Operating Expenses history runs 10 years deep, the most recent figure standing at $151.1 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 35.2% year-over-year to $151.1 million; the TTM figure through Mar 2026 stood at $563.8 million (up 49.36% YoY), while the FY2025 annual figure was $524.5 million, up 54.3% from the prior year.
• Operating Expenses was $151.1 million for Q1 2026 at Crinetics Pharmaceuticals, up from $139.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $151.1 million in Q1 2026 to a low of $37.0 million in Q1 2022.
• Historically, Operating Expenses has averaged $83.2 million across 5 years, with a median of $74.2 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses surged 66.68% in 2022, then increased 24.14% in 2023.
• A 5-year view of Operating Expenses shows it stood at $48.3 million in 2022, then grew by 29.82% to $62.7 million in 2023, then surged by 51.21% to $94.7 million in 2024, then soared by 47.58% to $139.8 million in 2025, then gained by 8.07% to $151.1 million in 2026.
• The last three Operating Expenses figures came in at $151.1 million (Q1 2026), $139.8 million (Q4 2025), and $142.7 million (Q3 2025), per Business Quant data.